ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 2464 • 2017 ACR/ARHP Annual Meeting

    Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life

    Jean Darloy1, René-Marc Flipo1, Nicolas Segaud2, Jean-Paul Eschard3, Vincent Goeb4, Jean-Hugues Salmon3, Eric Houvenagel5, Clément Chopin3, Samuel Gally6, David Pau7, Isabelle Idier8 and Guy Baudens9, 1Rheumatology, Rheumatology Department CHU Teaching Hospital Lille, Lille, France, 2Internal medicine, Internal Medicine Departement Armentières Hospital, Armentières, France, 3Rheumatology, Rheumatology Department CHU Teaching Hospital Reims, Reims, France, 4Rheumatologie, Rheumatology Department CHU Teaching Hospital Amiens, Amiens, France, 5Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, 6Clinical Operations, Roche SAS, Boulogne Billancourt, France, 7Statistics, Roche SAS, Boulogne Billancourt, France, 8Medical department, Chugai Pharma France, Paris La Defense, France, 9Rheumatology, Rheumatology Department CHR Valenciennes, Valenciennes, France

    Background/Purpose: It has been proven, in a pivotal RCT, that SC TCZ was non-inferior to IV TCZ [1]. However, the effectiveness of the SC TCZ…
  • Abstract Number: 447 • 2017 ACR/ARHP Annual Meeting

    Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis

    Levent Kilic1, Orhan Kucuksahin2, Zeynep Ozbalkan3, Cemal Bes4, Veli Yazisiz5, Ayten Yazici6, Dilek Solmaz7, Timucin Kasifoglu8 and Umut Kalyoncu9, 1Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, 3Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, 4Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 5Rheumatology, Akdeniz University Faculty of Medicine, Ankara, Turkey, 6Department of Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, 7Rheumatology, Katip Çelebi University Faculty of Medicine, İzmir, Turkey, 8Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 9Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: In general, retention rate in biological DMARDs represent both efficacy and safety. Tocilizumab (TOC) is a humanized monoclonal antibody that binds to the interleukin-6…
  • Abstract Number: 2469 • 2017 ACR/ARHP Annual Meeting

    Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study

    Ruediger Mueller1, Winfried Graninger2, Páris Sidiropoulos3, Christoph Goger4 and Johannes von Kempis5, 1Rheumatology, MD, St. Gallen, Switzerland, 2Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 3F. Hoffmann-La Roche Ltd, South San Francisco, CA, 4Roche Austria GmbH, Vienna, Austria, 5Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Background/Purpose: To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs…
  • Abstract Number: 453 • 2017 ACR/ARHP Annual Meeting

    The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis

    Alexander Pfeil1, Ottar Gadeholt2, Joachim Böttcher3, Diane Renz4, Peter Oelzner1 and Gunter Wolf1, 1Department of Internal Medicine III, Jena University Hospital, Jena, Germany, 2Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, 3Institut of Interventional and Diagnostic Radiology, SRH Waldklinikum Gera, Gera, Germany, 4Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Jena, Germany

    Background/Purpose: Digital X-ray Radiogrammetry (DXR) and Computer-Aided Joint Space Analysis (CAJSA) are established computer based techniques for the quantification of metacarpal bone mineral density and…
  • Abstract Number: 2474 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety of Extending Tocilizumab Infusion Intervals from 4 Weeks to 6 Weeks in Patients with Rheumatoid Arthritis

    Hiroshi Uda1 and Osamu Saiki2, 1Rheumatology, Higashiosaka City Medical Center, Higashiosaka, Japan, 2Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan

    Background/Purpose : A period of 4 weeks (w) has been recommended for rheumatoid arthritis (RA) patients as the interval between tocilizumab (TCZ, 8mg/kg) infusions. However,…
  • Abstract Number: 465 • 2017 ACR/ARHP Annual Meeting

    Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials

    Natasja Stæhr Gudman1, Pernille Juhl1, Christian S. Thudium2, Peter Junker3, Anne Sofie Siebuhr4, Inger Byrjalsen1, Morten Karsdal5 and Anne C. Bay-Jensen4, 1Nordic Bioscience, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Department of Rheumatology C, Odense University Hospital, Odense, Denmark, 4Rheumatology, Nordic Bioscience, Herlev, Denmark, 5Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular co-morbidity. The extra cellular matrix below the endothelial…
  • Abstract Number: 2475 • 2017 ACR/ARHP Annual Meeting

    Clinical Remission in Subjects with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab As Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: A Real-World Clinical Trial

    Raimon Sanmartí1, Emilio Martín-Mola2, João E. Fonseca3, Douglas J. Veale4, Alejandro Escudero-Contreras5 and Carlos M Gonzalez6, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital La Paz, Madrid, Spain, 3Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, 4Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 5Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: the primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) 162 mg weekly (qw) as…
  • Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study

    Seoyoung C. Kim1, Daniel H. Solomon1, James R. Rogers2, Sara Gale3, Micki Klearman3, Khaled Sarsour3 and Sebastian Schneeweiss2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Genentech, South San Francisco, CA

    Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
  • Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting

    MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Charles Peterfy1, Joel Kremer2, William F C Rigby3, Nora Singer4, Christine Birchwood5, Darcy Gill5, William Reiss5, Jinglan Pei5 and Margaret Michalska5, 1Spire Sciences, Inc., Boca Raton, FL, 2Albany Medical College, Albany, NY, 3Geisel School of Medicine at Dartmouth, Lebanon, NH, 4Case Western Reserve University School of Medicine, Cleveland, OH, 5Genentech, Inc., South San Francisco, CA

    Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
  • Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting

    Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study

    Anne C. Bay-Jensen1, Anne Sofie Siebuhr1, Christian S. Thudium2 and Morten Asser Karsdal1, 1Rheumatology, Nordic Bioscience, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
  • Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting

    Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice

    Dimitrios A. Pappas1, Carol J. Etzel2, Jennie Best3, Steve Zlotnick3, Taylor Blachley2, Gioia Persuitte2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 1426 • 2017 ACR/ARHP Annual Meeting

    Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Naoshi Nishina, Yuko Kaneko, Keiko Yoshimoto and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: We have already reported that baseline levels of soluble interluekin-6 receptor (sIL-6R), target of tocilizumab, predicted response to tocilizumab treatment in rheumatoid arthritis (RA)…
  • Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting

    Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies

    Alain Saraux1, René-Marc Flipo2, Bernard Combe3, Jacques Tebib4, Christelle Baffie5, Isabelle Idier6 and Alain Cantagrel7, 1Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 2Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 3Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 4Rheumatology, University Hospital, Hospices civils de Lyon, Lyon, France, 5Statistics, Altizem on behalf of Roche, Boulogne Billancourt, France, 6Medical department, Chugai Pharma France, Paris La Defense, France, 7Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France

    Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…
  • Abstract Number: 1467 • 2017 ACR/ARHP Annual Meeting

    Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab

    Cesar Diaz-Torné1, Paula Estrada2, Patricia Moya3, Maria A. Ortiz4, Diana de la Fuente5, Mireia Moreno6, Noemí Busquets7, Julio Ramírez8, Carme Moragues9, Sergi Ros5, Enrique Casado Burgos6, Vicente Torrente10, Elizabeth Garcia11, Manel Pujol12, Andrés Ponce13, Silvia Vidal4 and Juan José de Agustín14, 1Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 2Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Institut de Recerca Sant Pau, Barcelona, Spain, 5Rheumatology, Hospital de Viladecans, Viladecans, Spain, 6Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, 7Rheumatology, Hospital General de Granollers, Granollers, Spain, 8Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 9Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, L'Hospitalet de Llobregat, Spain, 11Rheumatology, Hospital de Mollet, Mollet, Spain, 12Hospital Mútua de Terrassa, Terrassa, Spain, 13Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, 14Rheumatology, Hospital Vall d´Hebrón, Barcelona, Spain

    Background/Purpose: Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling of IL-6/IL-6R complex, is an effective treatment in chronic inflammatory rheumatoid arthritis (RA).…
  • Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting

    Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial

    Xavier M Teitsma1, Johannes WG Jacobs1, Paco MJ Welsing2, Attila Pethö-Schramm3, Michelle EA Borm4, Jacob M. van Laar5, Floris PJ Lafeber5 and Johannes W.J. Bijlsma2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology